Login
Companies $FTH
$9.23 -$0.05 (0.54%) After hours
Faeth Therapeutics, Inc. logo

Faeth Therapeutics, Inc.

faeththerapeutics.com

What Do They Do?

Develops investigational cancer medicines, including PIKTOR, for patients with endometrial and breast cancer.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −346% (Loss)
vs −$4.6M in Q3 FY2025
  • Nov 9, 2026 Reported preliminary Phase 2 results for PIKTOR in endometrial cancer The company said the results support advancing PIKTOR toward a Phase 3 registrational trial, subject to regulatory alignment.
  • Jun 10, 2026 Appointed Anand Parikh chief executive and Brian Stephenson chief financial officer The company also changed its name to Faeth Therapeutics and its stock ticker to FTH.

From immune checkpoint antibodies to PIKTOR The older report centered on tumor-microenvironment antibodies aimed at immune signals. The latest report centers on PIKTOR, an oral combination that inhibits multiple nodes of a cancer pathway, for endometrial and breast cancer.

Who Do They Compete With?

Competes with Celcuity, Kazia Therapeutics, Relay Therapeutics, Eli Lilly, Novartis, Synnovation Therapeutics, OnKure Therapeutics, and Laekna Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support